Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab and Anlotinib with Chemo for Advanced Cervical Cancer
NCT04731038Phase 1Unknown
- Sponsor
- Ruijin Hospital
- Start
- Aug 2021
- Primary completion
- Jul 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of toripalimab and anlotinib in Cervical Cancer (CC), sponsored by Ruijin Hospital. Primary endpoint: Adverse Events at 36 months. Status: unknown.
02
Drugs
toripalimabanlotinib
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT04731038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04731038.